Jiangsu Nhwa Pharmaceutical Co Ltd
SZSE:002262
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
20.78
28.92
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CN |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SZSE:002262
|
24.1B CNY |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
992.9B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
541.8B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
278.2B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.3B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
223.2B CHF |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
269.1B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
151B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
97.1B EUR |
Loading...
|
Market Distribution
| Min | -409 046.1% |
| 30th Percentile | -1.4% |
| Median | 4.2% |
| 70th Percentile | 10.3% |
| Max | 876.4% |
Other Profitability Ratios
Jiangsu Nhwa Pharmaceutical Co Ltd
Glance View
Jiangsu Nhwa Pharmaceutical Co., Ltd. is an intriguing player in the pharmaceutical industry, operating with a robust focus on innovative therapeutic solutions. Headquartered in the bustling economic landscape of China, the company has carved a niche for itself primarily in the central nervous system (CNS) sector. Nhwa Pharmaceutical leverages advanced research and development to craft medications aimed at treating a variety of CNS disorders, including depression, schizophrenia, and epilepsy. This specialization in a highly complex and demanding field underscores the company's commitment to addressing some of the most challenging health issues faced by modern society. By advancing its expertise in this area, Nhwa ensures a steady stream of cutting-edge products that form the backbone of its revenue. The company's financial model strongly revolves around the development and commercialization of high-demand medications. Nhwa's revenues are primarily derived from domestic and international sales of its pharmaceuticals. It also invests considerably in maintaining a pipeline of products that are either in the development or regulatory approval stages. This strategic focus on a balanced product portfolio enables Nhwa to remain resilient against market fluctuations. Their investments in research are complemented by collaborations with academic institutions and other pharmaceutical enterprises, further amplifying their reach and competitiveness. This formula allows Nhwa Pharmaceutical to not only capture significant market share but also contribute meaningfully to the ongoing evolution of medical treatments in its chosen specialties.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Jiangsu Nhwa Pharmaceutical Co Ltd is 21.9%, which is below its 3-year median of 22.2%.
Over the last 3 years, Jiangsu Nhwa Pharmaceutical Co Ltd’s Operating Margin has decreased from 22.7% to 21.9%. During this period, it reached a low of 21.9% on Mar 31, 2025 and a high of 22.9% on Sep 30, 2024.